Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial

Area of Science:

• Phytomedicine
• Gastroenterology
• Infectious Diseases

Background:

• Helicobacter pylori infection is a global health concern requiring effective eradication strategies.
• Standard clarithromycin-based triple therapy faces challenges with resistance and variable efficacy.
• Exploring novel adjunctive therapies is crucial for improving H. pylori eradication rates.

Purpose of the Study:

• To investigate the efficacy of Salvia mirzayanii (S. mirzayanii) as an adjunctive treatment for H. pylori eradication.
• To assess the impact of S. mirzayanii on treatment side effects and patient compliance.
• To evaluate the potential of S. mirzayanii in enhancing clarithromycin-based triple therapy.

Main Methods:

• A randomized clinical trial involving 99 patients with H. pylori infection.
• Participants received either S. mirzayanii capsules or placebo for two weeks, in addition to clarithromycin-based triple therapy.
• Eradication rates, side effects, and compliance were assessed using both intention-to-treat and per-protocol analyses.

Main Results:

• The overall H. pylori eradication rate was 59.59%.
• Per-protocol analysis showed a significantly higher eradication rate in the S. mirzayanii group (84.62%) compared to placebo (P=0.026).
• No significant differences were observed in treatment side effects or medication compliance between groups.

Conclusions:

• Salvia mirzayanii may serve as a beneficial adjunctive therapy to improve H. pylori eradication rates.
• The findings suggest S. mirzayanii enhances the effectiveness of 14-day clarithromycin-based triple therapy.
• Further research is warranted to confirm these findings and elucidate the mechanisms of action.